Latest News

 Filter by Provider

Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today.

The Fed will be dealing with the worst of both worlds. Tariff-induced inflation and tariff-induced decline in national output.

Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd.

Highlighting the uncertainty that hangs over the US economy, first-quarter GDP nowcasts from two regional Fed banks report sharply different estimates.

Award-winning author Sam Ro: "Investing is like dieting: For many people, attempting to cut out junk food entirely just doesn't work."

Lucid Group Inc (NASDAQ:LCID) shares are trading higher on Monday in potential reaction to bullish commentary from a company executive.

With the Trump tariffs potentially sparking a toilet paper shortage, Kimberly-Clark could benefit, drawing eyes to KMB stock.

The spot level of VIX is truly inverted vis-à-vis the futures, but the overall curve is largely flattish.

Investor sentiment was shocked by Trump's 25% tariff on auto imports, increasing inflation fears. But some ETFs performed well, with gains up to 22.8%.

The Westwood LBRTY Global Equity ETF enables investors to overcome risks linked with economically unstable and corrupt regimes.

Cryptocurrency markets are trading in a tight sideways range on Monday as markets expect the impact of tariff announcements on Wednesday.

ETFs classified as Equity U.S. held 26.83% of the overall assets under management at the end of December 2024.

With tariffs coming for more countries in various amounts, a new tool from UPS could help global consumers know the increased prices better.

Sabra Healthcare REIT stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 78 to 82 Monday.

Goldman Sachs analyst shares key takeaways from 2025 Shoptalk Conference, highlighting conversational and personalized eCommerce, critical video content, and the role of AI in improving brand experience.

Investors should prepare for a 2008-style crisis.Benzinga warns of potential economic crisis predicted by Peter Schiff in 2008. Tariffs, rising interest rates, misguided Fed policy may cause trouble.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

In a welcome move, Stryker stock saw its Relative Strength Rating improve to 72 on Monday, up from 69 a day earlier.

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.

NNOX earnings call for the period ending December 31, 2024.

In today's session, these stocks are experiencing unusual volume.

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Allspring Global Investments launched two new actively managed ETFs (AGR, ASLV) to provide investors with access to mispriced stocks and value ideas.

Investors continue to brace for volatility ahead of U.S. President Donald Trump's tariff announcement this week. Fundstrat's Tom Lee believes bullish traders will get rewarded.

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).